TheCareerBridge.com’s Post

Want to learn what Business Development is like on the cutting-edge of cell therapy? Lucky for us, Amanda M. Rickard (Senior Manager Business Development at Notch Therapeutics) took time out of her busy schedule to fill us in! You can read the whole Q&A on the latest Science 2 Sales newsletter (link in the comments). Sneak peak below: 𝗔𝗻𝘆 𝗮𝗱𝘃𝗶𝗰𝗲 𝘁𝗼 𝘁𝗵𝗼𝘀𝗲 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘁𝗼 𝗺𝗮𝗸𝗲 𝘁𝗵𝗲 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗳𝗿𝗼𝗺 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁 𝘁𝗼 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁? "Talk to folks who have made the transition, to learn about the different types of roles that are available and how your unique background might be valuable. There are many different jobs that fit under the umbrella of BD, and it’s run differently across organizations, so getting diverse perspectives is important. This also helps build your network! I’d also look for opportunities to get exposed to BD before the transition, either through training or interacting with the BD folks at your organization to see where you might be able to help them - test the water to see if you like it and which skills you may need to develop." #careerdevelopment #science2sales #businessdevelopment

"Do you miss being in the lab, though?" I've had a lot of industry colleagues (scientists) ask about my transition to business development and whether it's an option for them, so I was glad for the chance to share some of my experience with Anis in his newsletter below! I hope it'll help those who are interested in exploring BD - just be prepared to answer the question above many, many times :).

#FastFacts now available! Reducing risk for cell therapy manufacturing with a battle-tested electroporation platform In this FastFacts, Andrew Mancini demonstrates how #electroporation technology can address key risk factors during the cell therapy manufacturing process. Watch the video or download the poster to learn about: • How choosing a clinically-validated manufacturing platform for critical steps such as cell electroporation can reduce risk during cell therapy manufacturing • A clinically-validated electroporation platform optimized for cell therapy manufacturing • How to address key risk factors during the #celltherapy manufacturing process, such as process variability, complexity, and product yield • The importance of robust, expert technical and regulatory support in enhancing risk mitigation Read the poster or watch the video below:

#FastFacts now available! Reducing risk for cell therapy manufacturing with a battle-tested electroporation platform In this FastFacts, Andrew Mancini demonstrates how #electroporation technology can address key risk factors during the #celltherapy manufacturing process. Watch the video or download the poster to learn about: • How choosing a clinically-validated manufacturing platform for critical steps such as cell electroporation can reduce risk during cell therapy manufacturing • A clinically-validated electroporation platform optimized for cell therapy manufacturing • How to address key risk factors during the cell therapy manufacturing process, such as process variability, complexity, and product yield • The importance of robust, expert technical and regulatory support in enhancing risk mitigation Read the poster or watch the video below:

#Article now available! How reducing labor time can save on your #celltherapy manufacturing costs In the early clinical development stage of autologous cell therapy manufacture, labor costs often dominate the overall cost of goods sold. In this article, Yen Kong (Field Application Scientist for Cell Therapy, USCAN Cytiva), Jeeheon Kang (GM Cell Therapy FAS Leader, APAC Cytiva), Janôt Schoep (Field Application Specialist for Cell Therapy, EMEA Cytiva) explain how to reduce labor time for certain critical steps of #autologous cell therapy manufacturing by using automated and closed systems. Read at your convenience below:

📢 Cutting Costs: Alder Therapeutics Revolutionizes Cell Therapy Manufacturing 📰 The company's trademarked AlderEdge™ approach aims to simplify and lower the cost of manufacturing therapeutic products, widening patient access. The founders' commercial vision and early consideration of market size and potential returns have helped attract investors. Alder Therapeutics is focused on optimizing and de-risking their process to ensure reliable manufacturing. #BioprocessUpdates #celltherapy #manufacturing #costeffective #AlderTherapeutics #AlderEdge #therapydevelopment #pluripotentstemcells #patientaccess #commercialvision #marketpotential #investors #optimization #derisking #reliablemanufacturing ▷ Read the full article here: 📎 https://lnkd.in/dfxDg4Ju

𝐈𝐧𝐭𝐞𝐧𝐬𝐢𝐭𝐲-𝐦𝐨𝐝𝐮𝐥𝐚𝐭𝐞𝐝 𝐑𝐚𝐝𝐢𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐌𝐚𝐣𝐨𝐫 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 𝐒𝐮𝐫𝐠𝐞 𝐏𝐫𝐞𝐝𝐢𝐜𝐭𝐞𝐝, 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲, 𝐛𝐲 2028 Download PDF Brochure@ https://lnkd.in/dXiwejrW The global size of intensity modulated radiotherapy market in terms of revenue was estimated to be worth $2.2 billion in 2023 and is poised to reach $2.8 billion by 2028, growing at a CAGR of 5.2% from 2023 to 2028. --> 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭: Siemens Healthineers AG (Germany), Elekta (Sweden), and Accuray Incorporated (US), among others. --> 𝐓𝐡𝐞 𝐎𝐭𝐡𝐞𝐫 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐓𝐡𝐢𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲: ViewRay, Inc. RaySearch Laboratories Varian Medical Systems Pacific Inc ZAP Surgical Systems, Inc. Xcision Medical Systems, LLC C-RAD AB IBA Mevion Medical Systems Brainlab Panacea Medical Technologies Pvt Ltd Nucletron Operations BV Brachytherapy Services, Inc IntraOp Medical Corporation Radiaction Ltd. CureMatch, Inc. Dignitana CureMetrix Genomic Health MagnetTx Oncology Solutions Ltd Otsuka Pharmaceutical Co., Ltd. Radial Health Quanta System Spa Vero Health, Inc. Digirad Edge Medical Medical Microinstruments, Inc.

Are you ready for the future of cell therapy manufacturing? Decentralized models are coming, but are you prepared to navigate the nuances or process and analytical development? Josh Ludwig discusses the path to GMP success leveraging Wilson Wolf Manufacturing, LLC, Bio-Technene and Fresenius Kabi products during a Phacilitate panel. Watch the panel: https://lnkd.in/eZca_ZYD #celltherapy #manufacturing #innovation

Oncology information system market Worth $11.1 billion by 2027 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://lnkd.in/dYh6NwWv The global oncology information system market in terms of revenue was estimated to be worth $7.7 billion in 2022 and is poised to reach $11.1 billion by 2027, growing at a CAGR of 7.6% from 2022 to 2027. Siemens Healthineers Elekta GE HealthCare McKesson Cerner Corporation Accuray Allscripts Healthcare, LLC IBM Pensionskasse der F. Hoffmann-La Roche AG EPIC Systems RaySearch Laboratories CureMD Bogardus Medical Systems, Inc Optum MICA Information Systems, Inc. Advanced Data Systems Corp EndoSoft Altai Oncology Solutions MIM Software

Decentralized cell therapy production sounds great, but it's riddled with complexities. Get an in-depth look at handling scalability, digital solutions, and more in a Phacilitate panel. Josh Ludwig discusses the path to GMP success leveraging Wilson Wolf Manufacturing, LLC, Bio-Techne and Fresenius Kabi products. https://lnkd.in/eZca_ZYD #celltherapymanufacturing #celltherapy